search
Back to results

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Primary Purpose

Advanced or Metastatic Solid Tumor Malignancies

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
NP-G2-044 Monotherapy
Anti-PD-1 Therapy
NP-G2-044 Combination therapy
Sponsored by
Novita Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced or Metastatic Solid Tumor Malignancies focused on measuring Advanced or Metastatic Solid Tumor Malignancies

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female ≥18 years of age;
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
  3. Able to swallow capsules;
  4. Adequate organ and bone marrow function, defined by the following:

    ANC >1500 cells/μL; Hemoglobin >9.0 g/dL; Platelet count >100,000 cells/μL; Total bilirubin ≤1.5 mg/dL; Albumin ≥3.0 g/dL; Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase ≤2.5 × upper limit of normal (ULN); Creatinine clearance ≥50 mL/min/1.73 m2; and Prothrombin time and partial thromboplastin time ≤1.5 × ULN.

  5. Female patients of childbearing potential must have a negative serum or urine pregnancy test at Screening and within 72 hours before the first dose of NP-G2-044. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required and must be negative for the patient to be eligible; Note: A woman is considered to be childbearing potential unless she is postmenopausal (≥1 year without menses and confirmed with a follicle-stimulating hormone [FSH] test) or surgically sterilized via bilateral oophorectomy, hysterectomy, bilateral tubal ligation, or successful Essure® placement with a documented confirmation test at least 3 months after the procedure.
  6. Male patients must be surgically sterile or willing to use a highly effective double-barrier contraception method (eg, male condom with diaphragm or male condom with cervical cap) upon study entry, while on NP-G2-044, and for a period of at least 4 months following the last dose of NP-G2-044; and
  7. Able to understand and voluntarily sign a written informed consent form (ICF) and willing and able to comply with protocol requirements.

Inclusion Criteria for NP-G2-044 Monotherapy:

Patients must meet all the following criteria to receive NP-G2-044 monotherapy in the study:

  1. Have a histopathologically confirmed advanced or metastatic solid tumor malignancy that is either treatment-refractory or otherwise ineligible for treatment with standard of care agents/regimens; and
  2. Have measurable disease per RECIST 1.1.; and
  3. For monotherapy expansion cohort (after the Mono-RP2D has been identified), patients must have:

    1. Gynecologic malignancies including ovarian, endometrial/uterine, fallopian tube, cervical, vulvar, and vaginal cancers; or
    2. Epidermal growth factor receptor (EGFR)-high (2+ or 3+ staining per DAKO criteria or genomic sequencing data showing 3 or more copies of the EGFR gene) triple-negative breast cancer (TNBC).

Inclusion Criterion for NP-G2-044 Combination Therapy Patients must meet the following criterion to receive NP-G2-044 in combination with anti-PD-1 therapy in the study:

1. Have initiated anti-PD-1 therapy in accordance with the package insert and have been receiving the anti-PD-1 therapy for ≥3 months (with therapy currently ongoing) and have stable disease, or had an initial period of stable disease and now have an initial scan demonstrating progressive disease per RECIST 1.1.

Exclusion Criteria:

  1. Received chemotherapy or radiotherapy within 4 weeks or 5 half-lives, whichever is shorter, of the first dose of NP-G2-044; Note: Prior immunotherapy is allowed for patients receiving NP-G2-044 monotherapy.
  2. Unresolved toxicities from previous anti-cancer therapy, defined as toxicities (other than NCI CTCAE v5.0 Grade ≤2 alopecia or neuropathy) not yet resolved to NCI CTCAE v5.0 Grade ≤1; Note: Patients who experienced a Grade ≥3 anti-PD-1-related AE per NCI CTCAE v5.0 are excluded unless recovered and reviewed by the Novita Medical Monitor or designee.
  3. Receiving any other investigational agent(s) or have received an investigational agent within 4 weeks of the first dose of NP-G2-044;
  4. Known untreated brain metastases or treated brain metastases that have not been radiographically and clinically stable (ie, not requiring steroids) ≥4 weeks prior to study enrollment;
  5. QTc by Fridericia method >470 msec or electrocardiogram (ECG) with evidence of clinically meaningful conduction abnormalities or active ischemia as determined by the Investigator;
  6. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, autoimmune or inflammatory diseases, or psychiatric illness/social situations that would limit compliance with study requirements;
  7. Pregnant, lactating, or is planning to attempt to become pregnant or impregnate someone during the study or within 90 days after dosing of NP-G2-044;
  8. Received prior allogenic hematopoietic stem cell transplantation or allogenic bone marrow transplantation;
  9. Received prior solid organ transplantation;
  10. Ongoing immunosuppressive therapy (≥10 mg/day of prednisone or its equivalent);
  11. Requires the use of a strong inhibitor or inducer of cytochrome P450 (CYP)3A4, CYP1A2, or CYP2D6 during the study;
  12. History of clinically meaningful gastrointestinal bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months of study enrollment; or
  13. Excluded by the Sponsor due to medical history, physical examination findings, clinical laboratory results, prior medications, or other entrance criteria.

Sites / Locations

  • Honor Health Research InstituteRecruiting
  • University of Arizona - Cancer CenterRecruiting
  • University of Arkansas for Medical SciencesRecruiting
  • City of HopeRecruiting
  • City of Hope Irvine LennarRecruiting
  • Hoag Memorial Hospital Presbyterian - Gynecologic Oncology AssociatesRecruiting
  • Nuvance HealthRecruiting
  • University of Florida (UF) - Shands Cancer CenterRecruiting
  • Indiana University (IU) Melvin and Bren Simon Cancer CenterRecruiting
  • University of Kansas Cancer CenterRecruiting
  • Henry Ford Health SystemRecruiting
  • Atlantic Health System - Morristown Medical CenterRecruiting
  • University of Cincinnati (UC) - Cancer InstituteRecruiting
  • University Hospitals Cleveland Medical CenterRecruiting
  • University of PennsylvaniaRecruiting
  • University of Texas SouthwesternRecruiting
  • Virginia Cancer SpecialistsRecruiting
  • Virginia Commonwealth University - Massey Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

NP-G2-044 Monotherapy- Capsule

NP-G2-044 Combination Therapy With Anti-PD-1 Therapy

Arm Description

NP-G2-044 capsule PO QD for each 28-day cycle

NP-G2-044 capsule PO QD for each 28-day cycle, Anti-PD-1 Therapy per standard of care, at a dose and frequency in accordance with the package insert

Outcomes

Primary Outcome Measures

Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D)
Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy
Will use NCI CTCAE v5.0
NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1
(computed tomography [CT] or magnetic resonance imaging [MRI])
Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapy
Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapy
Will use NCI CTCAE v5.0
NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-1 therapy assessed by RECIST 1.1
(computed tomography [CT] or magnetic resonance imaging [MRI])

Secondary Outcome Measures

Identify and characterize preliminary anti-tumor activity of NP-G2-044 in combination with anti-PD-1 therapy
Anti-tumor activity assessed using iRECIST
Pharmacokinetics (PK) of NP-G2-044 monotherapy: AUC
Area under the plasma concentration versus time curve
Pharmacokinetics (PK) of NP-G2-044 monotherapy: Tmax
Time to peak plasma concentration
Pharmacokinetics (PK) of NP-G2-044 monotherapy: Cmax
Peak plasma concentration
Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: AUC
Area under the plasma concentration versus time curve
Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: Tmax
Time to peak plasma concentration
Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: Cmax
Peak plasma concentration

Full Information

First Posted
July 30, 2021
Last Updated
August 8, 2023
Sponsor
Novita Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05023486
Brief Title
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Official Title
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 7, 2021 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novita Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced or Metastatic Solid Tumor Malignancies
Keywords
Advanced or Metastatic Solid Tumor Malignancies

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NP-G2-044 Monotherapy- Capsule
Arm Type
Experimental
Arm Description
NP-G2-044 capsule PO QD for each 28-day cycle
Arm Title
NP-G2-044 Combination Therapy With Anti-PD-1 Therapy
Arm Type
Experimental
Arm Description
NP-G2-044 capsule PO QD for each 28-day cycle, Anti-PD-1 Therapy per standard of care, at a dose and frequency in accordance with the package insert
Intervention Type
Drug
Intervention Name(s)
NP-G2-044 Monotherapy
Intervention Description
1600 mg QD and 2100 mg QD
Intervention Type
Drug
Intervention Name(s)
Anti-PD-1 Therapy
Intervention Description
previously initiated per standard of care, at a dose and frequency in accordance with the package insert
Intervention Type
Drug
Intervention Name(s)
NP-G2-044 Combination therapy
Intervention Description
1600 mg QD or 2100 mg QD
Primary Outcome Measure Information:
Title
Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D)
Time Frame
6 months
Title
Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy
Description
Will use NCI CTCAE v5.0
Time Frame
Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)
Title
NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1
Description
(computed tomography [CT] or magnetic resonance imaging [MRI])
Time Frame
24 months
Title
Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapy
Time Frame
9 months
Title
Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapy
Description
Will use NCI CTCAE v5.0
Time Frame
Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)
Title
NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-1 therapy assessed by RECIST 1.1
Description
(computed tomography [CT] or magnetic resonance imaging [MRI])
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Identify and characterize preliminary anti-tumor activity of NP-G2-044 in combination with anti-PD-1 therapy
Description
Anti-tumor activity assessed using iRECIST
Time Frame
24 months
Title
Pharmacokinetics (PK) of NP-G2-044 monotherapy: AUC
Description
Area under the plasma concentration versus time curve
Time Frame
6 months
Title
Pharmacokinetics (PK) of NP-G2-044 monotherapy: Tmax
Description
Time to peak plasma concentration
Time Frame
6 months
Title
Pharmacokinetics (PK) of NP-G2-044 monotherapy: Cmax
Description
Peak plasma concentration
Time Frame
6 months
Title
Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: AUC
Description
Area under the plasma concentration versus time curve
Time Frame
9 months
Title
Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: Tmax
Description
Time to peak plasma concentration
Time Frame
9 months
Title
Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: Cmax
Description
Peak plasma concentration
Time Frame
9 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female ≥18 years of age; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Life expectancy of > 6 months; Abilty to swallow capsules and tablets; Adequate organ and bone marrow function, defined by the following: ANC >1500 cells/μL; Hemoglobin >9.0 g/dL; Platelet count >100,000 cells/μL; Total bilirubin ≤1.5 mg/dL; Albumin ≥3.0 g/dL; Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase ≤2.5 × upper limit of normal (ULN); Creatinine clearance ≥50 mL/min; and Prothrombin time and partial thromboplastin time ≤1.5 × ULN. Female patients of childbearing potential must have a negative serum or urine pregnancy test at Screening and within 24 hours (if urine test) or 72 hours (if serum test) before the first dose of NP-G2-044. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required and must be negative for the patient to be eligible; Note: A woman is considered to be childbearing potential unless she is postmenopausal (≥1 year without menses and confirmed with a follicle-stimulating hormone [FSH] test) or surgically sterilized via bilateral oophorectomy, hysterectomy, bilateral tubal ligation, or successful Essure® placement with a documented confirmation test at least 3 months after the procedure. Male patients must be surgically sterile or willing to use a highly effective double-barrier contraception method (eg, male condom with diaphragm or male condom with cervical cap) upon study entry, while on NP-G2-044, and for a period of at least 4 months following the last dose of NP-G2-044; and Able to understand and voluntarily sign a written informed consent form (ICF) and willing and able to comply with protocol requirements. Inclusion Criteria for NP-G2-044 Monotherapy: Patients must meet all the following criteria to receive NP-G2-044 monotherapy in the study: Have a histopathologically confirmed advanced or metastatic solid tumor malignancy for which standard therapies are no longer effective, not tolerated or ineligible for the patient to receive; Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.; For monotherapy expansion cohort A (after the Mono-RP2D has been identified), patients must have: Gynecologic malignancies including ovarian, endometrial/uterine, fallopian tube, cervical, vulvar, and vaginal cancers; or Epidermal growth factor receptor (EGFR)-high (2+ or 3+ staining per DAKO criteria or genomic sequencing data showing 3 or more copies of the EGFR gene) triple-negative breast cancer (TNBC). For Monotherapy Expansion Cohort B, patient must have advanced or metastatic solid tumors malignancy Inclusion Criteria for NP-G2-044 Combination Therapy Patients must meet 1 of the following criteria to receive NP-G2-044 in combination with anti-PD-1 therapy in the study: 1. Have initiated anti-PD-1 therapy in accordance with the package insert and have been receiving the anti-PD-1 therapy for ≥3 months (with therapy currently ongoing) and have stable disease, or had an initial period of stable disease and now have an initial scan demonstrating progressive disease per RECIST 1.1. or Have discontinued prior anti-programmed death-1/programmed death ligand-1 (PD- [L]1) therapy and are now eligible for de novo NP-G2-044 plus standard of care anti-PD 1 therapy. Exclusion Criteria: Received chemotherapy or radiotherapy within 4 weeks or 5 half-lives, whichever is shorter, of the first dose of NP-G2-044; Note: Prior immunotherapy is allowed for patients receiving NP-G2-044 monotherapy. Unresolved toxicities from previous anti-cancer therapy, defined as toxicities (other than NCI CTCAE v5.0 Grade ≤2 alopecia or neuropathy) not yet resolved to NCI CTCAE v5.0 Grade ≤1; Note: Patients who experienced a Grade ≥3 anti-PD-1-related AE per NCI CTCAE v5.0 are excluded unless recovered and reviewed by the Novita Medical Monitor or designee. Receiving any other investigational agent(s) or have received an investigational agent within 4 weeks of the first dose of NP-G2-044; Note: Patients who have progressed on NP-G2-044 treatment prior to this study are not eligible Known untreated brain metastases or treated brain metastases that have not been radiographically and clinically stable (ie, not requiring steroids) ≥4 weeks prior to study enrollment; QTc by Fridericia method >470 msec or electrocardiogram (ECG) with evidence of clinically meaningful conduction abnormalities or active ischemia as determined by the Investigator; Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, autoimmune or inflammatory diseases, or psychiatric illness/social situations that would limit compliance with study requirements; Pregnant, lactating, or is planning to attempt to become pregnant or impregnate someone during the study or within 90 days after dosing of NP-G2-044; Received prior allogenic hematopoietic stem cell transplantation or allogenic bone marrow transplantation; Received prior solid organ transplantation; Ongoing immunosuppressive therapy (≥10 mg/day of prednisone or its equivalent); Requires the use of a strong inhibitor or inducer of cytochrome P450 (CYP)3A4, CYP1A2, or CYP2D6 during the study; History of clinically meaningful gastrointestinal bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months of study enrollment; or Excluded by the Sponsor due to medical history, physical examination findings, clinical laboratory results, prior medications, or other entrance criteria.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kelley Arnold
Phone
+1 6159647375
Ext
7617367
Email
K.Arnold@medpace.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jillian Zhang, Ph.D.
Organizational Affiliation
Novita Pharmaceuticals, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Honor Health Research Institute
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nancy Stanisz
Phone
480-323-1350
Email
nstanisz@honorhealth.com
First Name & Middle Initial & Last Name & Degree
Frank Tsai, MD
Facility Name
University of Arizona - Cancer Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85719
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Megan Hodges
Phone
520-694-9058
Email
mhodges@email.arizona.edu
First Name & Middle Initial & Last Name & Degree
Jennifer Segar, MD
Facility Name
University of Arkansas for Medical Sciences
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maroof Zafar
Phone
501-686-8274
Ext
24576
Email
mkzafar@uams.edu
First Name & Middle Initial & Last Name & Degree
Michael Birrer, MD
Facility Name
City of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aruna Parikh
Phone
626-218-3419
Ext
83419
Email
arparikh@coh.org
First Name & Middle Initial & Last Name & Degree
Vincent Chung, MD
Facility Name
City of Hope Irvine Lennar
City
Irvine
State/Province
California
ZIP/Postal Code
92618
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elle Kim
Phone
949-723-9529
Email
hykim@coh.org
First Name & Middle Initial & Last Name & Degree
Vincent Chung, MD
Facility Name
Hoag Memorial Hospital Presbyterian - Gynecologic Oncology Associates
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lyle Villanueva
Phone
949-764-6586
Email
lyle.villanueva@hoag.org
First Name & Middle Initial & Last Name & Degree
Alberto Mendivil, MD
Facility Name
Nuvance Health
City
Norwalk
State/Province
Connecticut
ZIP/Postal Code
06856
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pramila Krumholtz
Phone
203-739-7997
Email
pramila.krumholtz@nuvancehealth.org
First Name & Middle Initial & Last Name & Degree
Richard Frank, MD
Facility Name
University of Florida (UF) - Shands Cancer Center
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nghi Lam
Phone
352-265-5329
Email
nghi.lam@cancer.ufl.edu
First Name & Middle Initial & Last Name & Degree
Thomas George, MD
Facility Name
Indiana University (IU) Melvin and Bren Simon Cancer Center
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Madison Parish
Phone
317-278-0170
Email
mpparish@iu.edu
First Name & Middle Initial & Last Name & Degree
Shadia Jalal, MD
Facility Name
University of Kansas Cancer Center
City
Fairway
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ankita Tiwari
Phone
913-588-2545
Email
atiwari@kumc.edu
First Name & Middle Initial & Last Name & Degree
Anup Kasi, MD, MPH
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Anastos
Phone
313-725-7858
Email
aanasto1@hfhs.org
First Name & Middle Initial & Last Name & Degree
Shirish Gadgeel, MD
Facility Name
Atlantic Health System - Morristown Medical Center
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07962
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nancy Ginder
Phone
800-247-9580
Email
Nancy.Ginder@atlantichealth.org
First Name & Middle Initial & Last Name & Degree
Angela Alistar, MD
Facility Name
University of Cincinnati (UC) - Cancer Institute
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kayla Webb
Phone
513-584-0599
Email
webb2ka@ucmail.uc.edu
First Name & Middle Initial & Last Name & Degree
Amanda Jackson, MD
Facility Name
University Hospitals Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley Campbell
Phone
800-641-2422
Email
Ashley.Campbell2@UHhospitals.org
First Name & Middle Initial & Last Name & Degree
Jason Brown, MD
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shavon Rochester
Phone
610-621-8497
Email
PerelmanGyn/OncResearchCoordinatorPool@uphs.upenn.edu
First Name & Middle Initial & Last Name & Degree
Janos Tanyi, MD
Facility Name
University of Texas Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martha Cruz
Phone
214-645-9831
Email
Martha.Cruz@UTSouthwestern.edu
First Name & Middle Initial & Last Name & Degree
Sanjay Chandrasekaran
Facility Name
Virginia Cancer Specialists
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Janice Alcaide
Phone
571-512-3771
Email
Janice.Alcaide@usoncology.com
First Name & Middle Initial & Last Name & Degree
Alexander Spira, MD
Facility Name
Virginia Commonwealth University - Massey Cancer Center
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Faith McFadden
Phone
804-628-0616
Email
masseysiit@vcu.edu
First Name & Middle Initial & Last Name & Degree
Andrew Poklepovic, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

We'll reach out to this number within 24 hrs